-
1
-
-
0028298721
-
Single dose pharmacokinetics of (S)-atenolol administered orally as a single enantiomer formulation and as a racemic mixture (Tenormin)
-
Clementi WA, Garvey TQ, Clifton GD, McCoy RA, Brandt S, Schwartz S. Single dose pharmacokinetics of (S)-atenolol administered orally as a single enantiomer formulation and as a racemic mixture (Tenormin). Chirality. 1994;6(3):169-174.
-
(1994)
Chirality
, vol.6
, Issue.3
, pp. 169-174
-
-
Clementi, W.A.1
Garvey, T.Q.2
Clifton, G.D.3
McCoy, R.A.4
Brandt, S.5
Schwartz, S.6
-
2
-
-
0027438370
-
Stereoselective HPLC bioanalysis of atenolol enantiomers in plasma: Application to a comparative human pharmacokinetic study
-
Egginger G, Lindner W, Karh S, Stoschitzky K. Stereoselective HPLC bioanalysis of atenolol enantiomers in plasma: application to a comparative human pharmacokinetic study. Chirality. 1993; 5: 506-512.
-
(1993)
Chirality
, vol.5
, pp. 506-512
-
-
Egginger, G.1
Lindner, W.2
Karh, S.3
Stoschitzky, K.4
-
3
-
-
33646152413
-
-
Montvale, NJ: Medical Economics Company, Inc
-
Physician's Desk Reference-PDR, 51st ed, Montvale, NJ: Medical Economics Company, Inc; 1999:1548.
-
(1999)
Physician's Desk Reference-PDR, 51st Ed
, pp. 1548
-
-
-
4
-
-
0026017927
-
Atenolol and ischemic heart disease: An overview
-
Cruickshank JM, McAinsh J. Atenolol and ischemic heart disease: an overview. Curr Med Res Opin. 1991;12:485-496.
-
(1991)
Curr Med Res Opin
, vol.12
, pp. 485-496
-
-
Cruickshank, J.M.1
McAinsh, J.2
-
5
-
-
0025946625
-
Atenolol: A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders
-
Wadworth AN, Murdoch D, Brogden RN. Atenolol: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs. 1991;42:468-510.
-
(1991)
Drugs
, vol.42
, pp. 468-510
-
-
Wadworth, A.N.1
Murdoch, D.2
Brogden, R.N.3
-
6
-
-
0024514133
-
Beta-blockers and primary prevention of coronary heart disease in patients with high blood pressure
-
Psaty BM, Koepsell TD, LoGerfo JP, et al. Beta-blockers and primary prevention of coronary heart disease in patients with high blood pressure. JAMA. 1989;261:2087-2094.
-
(1989)
JAMA
, vol.261
, pp. 2087-2094
-
-
Psaty, B.M.1
Koepsell, T.D.2
Logerfo, J.P.3
-
7
-
-
0018406414
-
Atenolol: A review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension
-
Heel RC, Brogden RN, Speight TM, Avery GS. Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. Drugs. 1979;17:425-460.
-
(1979)
Drugs
, vol.17
, pp. 425-460
-
-
Heel, R.C.1
Brogden, R.N.2
Speight, T.M.3
Avery, G.S.4
-
8
-
-
0018778649
-
Once daily atenolol (Tenormine) in the treatment of angina pectoris
-
Majid PA, van der Vijgh WJF, Wadeh R, van der Wall EE, Roos JP. Once daily atenolol (Tenormine) in the treatment of angina pectoris. Eur J Cardiol. 1979;9(6):419-35.
-
(1979)
Eur J Cardiol
, vol.9
, Issue.6
, pp. 419-435
-
-
Majid, P.A.1
Van Der Vijgh, W.J.F.2
Wadeh, R.3
Van Der Wall, E.E.4
Roos, J.P.5
-
9
-
-
0025882249
-
Bioequivalence of two atenolol formulations in healthy volunteers. Evaluation and prediction of effect kinetics at β-adrenoceptors in vivo by means of a radioreceptor assay
-
Sitzler G, Heibel B, Lucker PW, Palm D. Bioequivalence of two atenolol formulations in healthy volunteers. Evaluation and prediction of effect kinetics at β-adrenoceptors in vivo by means of a radioreceptor assay. Methods Find Exp Clin Pharmacol. 1991;13(2):129-137.
-
(1991)
Methods Find Exp Clin Pharmacol
, vol.13
, Issue.2
, pp. 129-137
-
-
Sitzler, G.1
Heibel, B.2
Lucker, P.W.3
Palm, D.4
-
10
-
-
0018741249
-
Atenolol determination by high-performance liquid chromatography and fluorescence detection
-
Yee YG, Ruben P, Blaschke TF. Atenolol determination by high-performance liquid chromatography and fluorescence detection. J Chromatogr. 1993;171:357-362.
-
(1993)
J Chromatogr
, vol.171
, pp. 357-362
-
-
Yee, Y.G.1
Ruben, P.2
Blaschke, T.F.3
-
11
-
-
0025806675
-
Quantitative analysis of beta-blockers in human plasma by reversed-phase ion-pair high-performance liquid chromatography using a micropore column
-
Shen J, Wanwimolruk S, Hung C T, Zoest AR. Quantitative analysis of beta-blockers in human plasma by reversed-phase ion-pair high-performance liquid chromatography using a micropore column. J Liq chromatogr. 1991;14:777-793.
-
(1991)
J Liq Chromatogr
, vol.14
, pp. 777-793
-
-
Shen, J.1
Wanwimolruk, S.2
Hung, C.T.3
Zoest, A.R.4
-
12
-
-
0026341602
-
A liquid chromatographie method for determination of atenolol in human plasma
-
Terry S, Teitelbaum Z. A liquid chromatographie method for determination of atenolol in human plasma. J Liq Chromatogr. 1991;1:3735-3744.
-
(1991)
J Liq Chromatogr
, vol.1
, pp. 3735-3744
-
-
Terry, S.1
Teitelbaum, Z.2
-
13
-
-
0030748837
-
Comparative bioavailability of two atenolol tablet formulations after a single dose administration
-
Martins ML, Pierossi MA, Moraes LA, et al. Comparative bioavailability of two atenolol tablet formulations after a single dose administration. Int J Clin Pharm Ther. 1997;35(8):324-328.
-
(1997)
Int J Clin Pharm Ther
, vol.35
, Issue.8
, pp. 324-328
-
-
Martins, M.L.1
Pierossi, M.A.2
Moraes, L.A.3
-
14
-
-
0033799885
-
Comparative bioavailability of two formulations containing atenolol and chlortalidone associated in a 4:1 fixed combination
-
Marzo A, Monti NC, Dal Bo L, et al. Comparative bioavailability of two formulations containing atenolol and chlortalidone associated in a 4:1 fixed combination. Arzneimittelforschung. 2000;50(9):802-808.
-
(2000)
Arzneimittelforschung
, vol.50
, Issue.9
, pp. 802-808
-
-
Marzo, A.1
Monti, N.C.2
Dal Bo, L.3
-
15
-
-
33646132831
-
Rapid and simultaneous analysis of seven beta-blockers in human plasma using electrospray LC/MS/MS
-
Li J, Anari R, Kwok D. Rapid and simultaneous analysis of seven beta-blockers in human plasma using electrospray LC/MS/MS. AAPS PharmSci. 1999;1(4). Abstract 2854.
-
(1999)
AAPS PharmSci
, vol.1
, Issue.4
, pp. 2854
-
-
Li, J.1
Anari, R.2
Kwok, D.3
-
16
-
-
0005918751
-
Bioavailability and bioequivalence requirements
-
Food and Drug Administration. Bioavailability and bioequivalence requirements. Fed Regist. 1985;320:154-173.
-
(1985)
Fed Regist
, vol.320
, pp. 154-173
-
-
-
17
-
-
0032547907
-
Bioavailability and bioequivalence requirements; abbreviated applications; proposed revisions
-
Food and Drug Administration. Bioavailability and bioequivalence requirements; abbreviated applications; proposed revisions. Proposed rule. Fed Regist. 1998;63:64222-64228.
-
(1998)
Proposed Rule. Fed Regist
, vol.63
, pp. 64222-64228
-
-
-
18
-
-
55449115713
-
Guidance for industry, bioanalytical methods validation for human studies
-
Food and Drug Administration. Guidance for industry, bioanalytical methods validation for human studies. Food and Drug Administration Web site. Available at: http://www.fda.gov./cder/guidance/,1998b. August/1998.
-
Food and Drug Administration Web Site
-
-
-
19
-
-
0000488030
-
In vivo bioequivalence guidances
-
Food and Drug Administration. In vivo bioequivalence guidances. Pharmacopeial Forum. 1993;19:6501-6508.
-
(1993)
Pharmacopeial Forum
, vol.19
, pp. 6501-6508
-
-
|